NCT03502681 2022-07-01A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer PatientsBig Ten Cancer Research ConsortiumPhase 1 Terminated6 enrolled 12 charts
NCT01126749 2022-02-28Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder CancerEisai Inc.Phase 1/2 Terminated92 enrolled 15 charts